Clinical Trial Update: A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 study investigating panitumumab in patients with cetuximab-refractory metastatic colorectal cancer is ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Panitumumab (panitumumab)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: UNKNOWN